By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Goldman Sachs today upgraded PerkinElmer and Affymetrix but downgraded Thermo Fisher Scientific.

In a report outlining its outlook for 2012 in the broad medical technology space, analysts Isaac Ro and David Roman upgraded the investment firm's rating for PerkinElmer to Buy from Neutral, saying changes it has made in recent years has left it well positioned in the coming year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.

George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.

A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.

The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.